Analyst picks & changes

Interneuron Pharmaceuticals Inc.


Patricia Lea of Vector Securities International initiated coverage with a "buy." She said the stock is likely to rise suddenly this year when the FDA announces that its Endocrine

Read the full 331 word article

How to gain access

Continue reading with a
two-week free trial.